Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Key highlights
  • SYNCHRONIZE-1 (76 weeks) showed sustained weight loss up to 16.6% using the efficacy estimand versus 3.2% with placebo.
  • In a SYNCHRONIZE-1 substudy, survodutide reduced visceral fat by up to 34.0% and liver fat by up to 63.1%, while lean mass loss represented no more than 10.8% of total tissue-mass change at the highest dose.
  • SYNCHRONIZE-MASLD (48 weeks) met co-primary endpoints: up to 84.2% of survodutide-treated participants achieved ≥30% relative liver fat reduction versus 24.3% on placebo, and up to 12.2% relative body-weight reduction versus 1.0% on placebo.
  • Secondary MASLD results: 61.0% of treated patients reached liver fat normalization (<5%) versus 5.7% on placebo; most common adverse events were GI-related with 19% treatment discontinuation due to GI events versus 2.9% for placebo, and no new safety signals identified.

Overview

Boehringer Ingelheim reported positive Phase III results for survodutide (BI 456906), a glucagon/GLP-1 dual agonist, from two trials: SYNCHRONIZE-1 in adults with overweight or obesity without type 2 diabetes (76 weeks), and SYNCHRONIZE-MASLD in adults with overweight or obesity and MASLD with evidence of inflammation and/or fibrosis (48 weeks). Full data were presented at the ADA 2026 Scientific Sessions and published in The New England Journal of Medicine and Nature Medicine.

SYNCHRONIZE-1: body composition and liver fat

The 76-week trial met primary endpoints with sustained weight loss up to 16.6% (efficacy estimand) versus 3.2% for placebo. An MRI-based substudy showed targeted fat loss: visceral fat reduced up to 34.0% and liver fat up to 63.1%. Lean mass loss at the highest dose accounted for no more than 10.8% of the total tissue-mass change, indicating weight loss was primarily fat-driven.

SYNCHRONIZE-MASLD: liver outcomes

The 48-week MASLD trial met both co-primary endpoints: up to 84.2% of participants on survodutide achieved a ≥30% relative reduction in liver fat versus 24.3% with placebo, and body-weight fell up to 12.2% versus 1.0% on placebo. A secondary endpoint showed 61.0% reached liver fat normalization (<5%) versus 5.7% on placebo, with favorable trends in liver biomarkers such as ALT.

Safety and programme next steps

Gastrointestinal events were the most common adverse events, mostly mild to moderate and occurring during dose escalation; discontinuations due to GI events were 19% for survodutide versus 2.9% for placebo. No new safety signals were identified. Survodutide remains investigational; Boehringer is advancing Phase IIIb studies (SYNCHRONIZE-HERA, ELEVATE-LIVER, SYNCHRONIZE-START) and larger Phase III trials (LIVERAGE and LIVERAGE-Cirrhosis) to address additional clinical questions.

Source: Boehringer Ingelheim

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

28 October 2026
Boehringer Ingelheim reports survodutide meets cardiovascular safety endpoint

The Phase III trial found no increased risk of major cardiovascular events versus placebo, alongside improvements in weight, blood pressure and waist circumference.

1 October 2026
Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes

At 76 weeks, weight loss reached 13.1%, HbA1c fell by up to 1.21%, and gastrointestinal events led 18% of treated participants to discontinue.

28 April 2026
Boehringer Ingelheim’s survodutide achieves 16.6% weight loss in Phase III obesity trial

Trial met co-primary endpoints; 85.1% achieved ≥5% weight loss vs 38.8% placebo; weight loss mainly fat with reduced waist circumference; GI events were mild–moderate; MASH trials ongoing

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.

9 November 2026
Merck reports positive Phase 2b efinopegdutide data in MASH with F2–F3 fibrosis

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.